Published online Dec 26, 2021. doi: 10.12998/wjcc.v9.i36.11173
Peer-review started: May 11, 2021
First decision: July 8, 2021
Revised: August 3, 2021
Accepted: November 15, 2021
Article in press: November 15, 2021
Published online: December 26, 2021
Hyponatremia in chronic hypothyroidism is commonly seen in clinical practice. However, the association between hyponatremia and acute hypothyroidism is unclear. Acute hypothyroidism is usually seen in patients who undergo preparation for radioactive iodine therapy.
The incidence and influencing factors of hyponatremia before 131I treatment in China are still unclear. This article will offer our center's experience of the management of thyroid cancer patients prior to 131I therapy.
To improve patient management during the preparation period for 131I treatment. The cause of hyponatremia was not further investigated in this study. Thus, further studies with larger sample sizes, including prospective studies, are needed in the future to verify these results.
An observational study design was used in this clinical study. Patients with and without hyponatremia were studied by univariate and multivariate analysis. The sample size in this study was larger than those reported in previous publications.
The incidence of hyponatremia induced by 131I treatment preparation was not high (2.5%). Twenty-three (2.5%) patients were diagnosed with hyponatremia before 131I treatment, including 21 cases (91.3%) of mild hyponatremia and 2 cases (8.7%) of moderate hyponatremia.
This study indicates that preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients.
Measurement of sodium post-radioactive iodine therapy should be considered in patients.